Erytech begins Phase II trial of eryaspase to treat ALL
French biopharmaceutical firm Erytech Pharma has begun a Phase II clinical trial of eryaspase (GRASPA) for the treatment of patients with acute lymphoblastic leukaemia (ALL).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Clinical Trials | Leukemia | Pharmaceuticals